English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy

MPS-Authors
/persons/resource/persons145979

Murgia,  Marta
Mann, Matthias / Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Max Planck Society;

/persons/resource/persons78356

Mann,  Matthias
Mann, Matthias / Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Max Planck Society;

External Ressource
No external resources are shared
Fulltext (public)

562.full.pdf
(Any fulltext), 3MB

Supplementary Material (public)
There is no public supplementary material available
Citation

Gramlich, M., Pane, L. S., Zhou, Q., Chen, Z., Murgia, M., Schötterl, S., et al. (2015). Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy. EMBO MOLECULAR MEDICINE, 7(5), 562-576. doi:10.15252/emmm.201505047.


Cite as: http://hdl.handle.net/11858/00-001M-0000-0027-A793-8
Abstract
Frameshift mutations in the TTN gene encoding titin are a major cause for inherited forms of dilated cardiomyopathy (DCM), a heart disease characterized by ventricular dilatation, systolic dysfunction, and progressive heart failure. To date, there are no specific treatment options for DCM patients but heart transplantation. Here, we show the beneficial potential of reframing titin transcripts by antisense oligonucleotide (AON)-mediated exon skipping in human and murine models of DCM carrying a previously identified autosomal-dominant frameshift mutation in titin exon 326. Correction of TTN reading frame in patient-specific cardiomyocytes derived from induced pluripotent stem cells rescued defective myofibril assembly and stability and normalized the sarcomeric protein expression. AON treatment in Ttn knock-in mice improved sarcomere formation and contractile performance in homozygous embryos and prevented the development of the DCM phenotype in heterozygous animals. These results demonstrate that disruption of the titin reading frame due to a truncating DCM mutation canbe restored by exon skipping in both patient cardiomyocytes invitro and mouse heart invivo, indicating RNA-based strategies as a potential treatment option for DCM.